Hansa Biopharma Valuation
| HNSA Stock | SEK 30.68 0.80 2.68% |
At this time, the firm appears to be fairly valued. Hansa Biopharma AB retains a regular Real Value of kr30.06 per share. The prevalent price of the firm is kr30.68. Our model calculates the value of Hansa Biopharma AB from evaluating the firm fundamentals such as Shares Outstanding of 52.44 M, return on equity of -0.89, and Return On Asset of -0.27 as well as inspecting its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Hansa Biopharma's price fluctuation is not too volatile at this time. Calculation of the real value of Hansa Biopharma AB is based on 3 months time horizon. Increasing Hansa Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Hansa Biopharma's intrinsic value may or may not be the same as its current market price of 30.68, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 30.68 | Real 30.06 | Hype 30.68 | Naive 32.9 |
The intrinsic value of Hansa Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Hansa Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Hansa Biopharma AB helps investors to forecast how Hansa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Hansa Biopharma more accurately as focusing exclusively on Hansa Biopharma's fundamentals will not take into account other important factors: Hansa Biopharma Total Value Analysis
Hansa Biopharma AB is currently anticipated to have takeover price of 2.17 B with market capitalization of 2.82 B, debt of 783.93 M, and cash on hands of 762.73 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Hansa Biopharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.17 B | 2.82 B | 783.93 M | 762.73 M |
Hansa Biopharma Investor Information
About 41.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 13.1. Hansa Biopharma AB had not issued any dividends in recent years. The entity had 1015:964 split on the 16th of March 2015. Based on the key measurements obtained from Hansa Biopharma's financial statements, Hansa Biopharma AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Hansa Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Hansa Biopharma has an asset utilization ratio of 9.16 percent. This implies that the Company is making kr0.0916 for each dollar of assets. An increasing asset utilization means that Hansa Biopharma AB is more efficient with each dollar of assets it utilizes for everyday operations.Hansa Biopharma Ownership Allocation
Hansa Biopharma AB has a total of 52.44 Million outstanding shares. 30% of Hansa Biopharma AB outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Hansa Biopharma Profitability Analysis
The company reported the revenue of 154.53 M. Net Loss for the year was (609.57 M) with profit before overhead, payroll, taxes, and interest of 116.05 M.About Hansa Biopharma Valuation
The stock valuation mechanism determines Hansa Biopharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Hansa Biopharma AB based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Hansa Biopharma. We calculate exposure to Hansa Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Hansa Biopharma's related companies.Hansa Biopharma AB , a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. Hansa Biopharma AB was founded in 2001 and is headquartered in Lund, Sweden. Hansa Biopharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 60 people.
8 Steps to conduct Hansa Biopharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Hansa Biopharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Hansa Biopharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Hansa Biopharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Hansa Biopharma's revenue streams: Identify Hansa Biopharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Hansa Biopharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Hansa Biopharma's growth potential: Evaluate Hansa Biopharma's management, business model, and growth potential.
- Determine Hansa Biopharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Hansa Biopharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Hansa Stock Analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.